Seroprevalence of SARS‐CoV‐2 Antibodies and Associated Factors in Bamako, Mali: A Population‐Based Cross‐Sectional Study in September 2022
Influenza and Other Respiratory Viruses · 2024
DOI: 10.1111/irv.13343 ↗Kurz gefasst
Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Bourama Traoré und 25 weiteren Autor:innen. Beteiligte Einrichtung: International Center for Excellence in Research (ICER), Faculty of Medicine and Odontostomatology (FMOS), Faculty of Pharmacy (FAPHA), University Cli…. Hauptthemen laut MEDLINE: COVID-19, Antibodies, Viral, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: WHO/Afro, WHO Unity Studies, FIC NIH HHS.
Abstract (Originalsprache)
Background
The sero‐epidemiological characteristics of SARS‐CoV‐2 infections in Mali are not yet well understood. This study assessed SARS‐CoV‐2 antibody seroprevalence and factors associated with antibody responses in the general population of Bamako, the capital city and epicenter of COVID‐19, to assess the magnitude of the pandemic and contribute to control strategy improvements in Mali.
Methods
A cross‐sectional survey was conducted in September 2022 to collect sociodemographic information, clinical characteristics, comorbid factors, and blood samples. ELISA was performed to determine anti‐Spike (anti‐S) and anti‐RBD antibody levels. A total of 3601 participants were enrolled in REDCap. R‐Studio was used for the statistical analysis. The chi‐squared (χ 2 ) test was used to compare the proportions across different groups. Logistic regression models were used to elucidate factors associated with antibody responses.
Result
The sex ratio for female‐to‐male was 3.6:1. The most representative groups were the 20–29‐year‐olds (28.9%, n = 1043) and the 30–39‐year‐olds (26.9%, n = 967). The COVID‐19 vaccine coverage among the participants was 35.8%, with vaccines from Covishield AstraZeneca (13.4%), Johnson & Johnson (16.7%), Sinovac (3.9%), and BioNTech Pfizer (1.8%). Overall, S protein and RBD antibody seroprevalences were remarkably high in the study population (98% and 97%, respectively). Factors such as youth (1–9 years old) and male sex were associated with lower SARS‐CoV‐2 antibody responses, whereas COVID‐19 vaccinations were associated with increased antibody responses.
Conclusion
This serosurvey demonstrated the high seroprevalence of SARS‐CoV‐2 antibodies and highlighted the factors influencing antibody responses, while clearly underlining an underestimation of the pandemic in Mali.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- International Center for Excellence in Research (ICER), Faculty of Medicine and Odontostomatology (FMOS), Faculty of Pharmacy (FAPHA), University Clinical Research Center (UCRC) at the University of Sciences, Techniques…
- Center for Polymers and Organic Solids, Department of Chemistry and Biochemistry, University of California Santa Barbara, Santa Barbara, California, USA.
- District Health Center of Commune 4 of Bamako, Minister of Health and Social Development of Mali, Bamako, Mali.
- Hospital District Health of Commune 1 of Bamako, Minister of Health and Social Development of Mali, Bamako, Mali.
- District Health Center of Commune 6 of Bamako, Minister of Health and Social Development of Mali, Bamako, Mali.
- District Health Center of Commune 5 of Bamako, Minister of Health and Social Development of Mali, Bamako, Mali.
ORCID-Profile: Saidou Balam
Förderung
- WHO/Afro
- WHO Unity Studies
- FIC NIH HHS
- German Federal Ministry of Health
- COVID-19 Solidarity Response Fund
Zitieren
APA
Traoré, B., Guindo, M. A., Konaté, D., Kané, F., Incandela, N. C., Traore, A., Kanté, S., Sidibé, M., Keita, B., Kasse, F., Tangara, K., Diallo, D., Maiga, I. Y., Thiam, S., Cisse, A., Siby, K. M., Dicko, A. R., Goita, M., Kone, D., …, & Balam, S. (2024). Seroprevalence of SARS‐CoV‐2 Antibodies and Associated Factors in Bamako, Mali: A Population‐Based Cross‐Sectional Study in September 2022. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13343
Vancouver
Traoré B, Guindo MA, Konaté D, Kané F, Incandela NC, Traore A, et al. Seroprevalence of SARS‐CoV‐2 Antibodies and Associated Factors in Bamako, Mali: A Population‐Based Cross‐Sectional Study in September 2022. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.13343
BibTeX
@article{Traor2024,
author = {Traoré, Bourama and Guindo, Merepen A and Konaté, Drissa and Kané, Fousseyni and Incandela, Nathan C and Traore, Abdouramane and Kanté, Salimata and Sidibé, Mariam and Keita, Bourama and Kasse, Fatoumata and Tangara, Karamoko and Diallo, Dramane and Maiga, Issoufi Y and Thiam, Salif and Cisse, Abdourhamane and Siby, Khatry M and Dicko, Abdoul R and Goita, Mariam and Kone, Diakaridia and Diallo, Mamadou and Traore, Modibo and Coulibaly, Yaya I and Diakité, Mahamadou and Doumbia, Seydou and Dolo, Housseini and Balam, Saidou},
title = {Seroprevalence of SARS‐CoV‐2 Antibodies and Associated Factors in Bamako, Mali: A Population‐Based Cross‐Sectional Study in September 2022},
journal = {Influenza and Other Respiratory Viruses},
year = {2024},
doi = {10.1111/irv.13343}
}
EUVIMED